Lack of correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in non-small cell lung cancer assessed by 18F- fluoromisonidazole and 18F-FDG PET

Journal of Nuclear Medicine

Volumn 47, Issue 12, 2006, Pages 1921-1926

  Cherk, Martin H ^a   Foo, Serene S ^a   Poon, Aurora M T ^a   Knight, Simon R ^a   Murone, Carmel ^a   Papenfuss, Anthony T ^b   Sachinidis, John I ^a   Saunder, Timothy H C ^a   O'Keefe, Graeme J ^a   Scott, Andrew M ^a  

^a AUSTIN HOSPITAL   (Australia)

^b WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Immunohistochemistry; Non small cell lung cancer; PET; Tumor hypoxia; Vascular endothelial growth factor

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; FLUORODEOXYGLUCOSE F 18; 1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; DIAGNOSTIC AGENT; DRUG DERIVATIVE; GLUCOSE; MISONIDAZOLE; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CELL FRACTIONATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG UPTAKE; FEMALE; GLUCOSE METABOLISM; HUMAN; HYPOXIA; HYPOXIC CELL; LUNG NON SMALL CELL CANCER; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; CELL HYPOXIA; COMPARATIVE STUDY; LUNG TUMOR; METABOLIC CLEARANCE RATE; METABOLISM; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY); SCINTISCANNING; STATISTICS;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; CELL HYPOXIA; FLUORODEOXYGLUCOSE F18; GLUCOSE; HUMANS; LUNG NEOPLASMS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MISONIDAZOLE; NEOVASCULARIZATION, PATHOLOGIC; RADIOPHARMACEUTICALS; STATISTICS;

EID: 34547883821     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Kim SJ, Rabbani ZN, Dewhirst MW, et al. Expression of HIF-1alpha, CA IX, VEGF, and MMP-9 in surgically resected non-small cell lung cancer. Lung Cancer. 2005;49:325-335.
2. Le QT, Chen E, Salim A, et al. An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers. Clin Cancer Res. 2006;12:1507-1514.
3. Koukourakis MI, Giatromanolaki A, Sivridis E, et al. Lactate dehydrogenase-5 (LDH-5) overexpression in non-small-cell lung cancer tissues is linked to tumour hypoxia, angiogenic factor production and poor prognosis. Br J Cancer. 2003;89:877-885.
4. Gray LH, Conger AD, Ebert M, Hornsey S, Scott OC. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol. 1953;26:638-648.
5. Lewis JS, Welch MJ. PET imaging of hypoxia. Q J Nucl Med. 2001;45:183-188.
6. 18F-FDG PET, and immunohistochemical studies. J Nucl Med. 2006;47:410-418.
7. Hicks RJ, Rischin D, Fisher R, Binns D, Scott AM, Peters LJ. Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent. Eur J Nucl Med Mol Imaging. 2005;32:1384-1391.
8. 18F-fluoromisonidazole positron emission tomography. BJU Int. 2005;96:540-546.
9. 180F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med. 2005;46:253-260.
10. Koh WJ, Bergman KS, Rasey JS, et al. Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18] fluoromisonidazole positron emission tomography. Int J Radiat Oncol Biol Phys. 1995;33:391-398.
11. 18F] fluorodeoxyglucose positron emission tomography in response evaluation after chemo-/radiotherapy of non-small-cell lung cancer: a feasibility study. BMC Cancer. 2006;6:51.
12. 18F-fluoromisonidazole positron emission tomography after ischemic stroke. Ann Neurol. 2000;48:228-235.
13. 18F-fluoromisonidazole. Neurology. 1998;51:1617-1621.
14. 18F- Fluorodeoxyglucose positron emission tomography in evaluation of germ cell tumor after chemotherapy. Urology. 2004;64:1202-1207.
15. Spiro SG, Silvestri GA. The treatment of advanced non-small cell lung cancer. Curr Opin Pulm Med. 2005;11:287-291.
16. Dachs GU, Tozer GM. Hypoxia modulated gene expression: angiogenesis, metastasis and therapeutic exploitation. Eur J Cancer. 2000;36(13):1649-1660.
17. Tsang RW, Fyles AW, Milosevic M, et al. Interrelationship of proliferation and hypoxia in carcinoma of the cervix. Int J Radiat Oncol Biol Phys. 2000;46:95-99.
18. Nordsmark M, Bentzen SM, Overgaard J. Measurement of human tumour oxygenation status by a polarographic needle electrode: an analysis of inter- and intratumour heterogeneity. Acta Oncol. 1994;33:383-389.
19. Foo SS, Abbott DF, Lawrentschuk N, Scott AM. Functional imaging of intratumoral hypoxia. Mol Imaging Biol. 2004;6:291-305.
20. Hockel M, Vaupel P. Biological consequences of tumor hypoxia. Semin Oncol. 2001; 28(2 suppl 8)36-41.
21. Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 1996;56:4509-4515.
22. Koch CJ, Evans SM. Non-invasive PET and SPECT imaging of tissue hypoxia using isotopically labeled 2-nitroimidazoles. Adv Exp Med Biol. 2003;510:285-292.
23. Rasey JS, Nelson NJ, Chin L, Evans ML, Grunbaum Z. Characteristics of the binding of labeled fluoromisonidazole in cells in vitro. Radiat Res. 1990;122:301-308.
24. Rasey JS, Grunbaum Z, Magee S, et al. Characterization of radio-labeled fluoromisonidazole as a probe for hypoxic cells. Radiat Res. 1987;111:292-304.
25. Graham MM, Peterson LM, Link JM, et al. Fluorine-18-fluoromisonidazole radiation dosimetry in imaging studies. J Nucl Med. 1997;38:1631-1636.
26. Swinson DE, Jones JL, Cox G, Richardson D, Harris AL, O'Byrne KJ. Hypoxia-inducible factor-1 alpha in non small cell lung cancer: relation to growth factor, protease and apoptosis pathways. Int J Cancer. 2004;111:43-50.
27. Giatromanolaki A, Koukourakis MI, Sivridis E, et al. Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. Br J Cancer. 2001;85:881-890.
28. Volm M, Koomagi R. Hypoxia-inducible factor (HIF-1) and its relationship to apoptosis and proliferation in lung cancer. Anticancer Res. 2000;20:1527-1533.
29. Volm M, Koomagi R, Mattern J. Interrelationships between microvessel density, expression of VEGF and resistance to doxorubicin of non-small lung cell carcinoma. Anticancer Res. 1996;16:213-217.
30. Zhang H, Zhang Z, Xu Y, et al. The expression of hypoxia inducible factor 1-alpha in lung cancer and its correlation with P53 and VEGF. J Huazhong Univ Sci Technolog Med Sci. 2004;24:124-127.
31. Choy H, Nabid A, Stea B, et al. Phase II multicenter study of induction chemotherapy followed by concurrent efaproxiral (RSR13) and thoracic radiotherapy for patients with locally advanced non-small-cell lung cancer. J Clin Oncol. 2005;23:5918-5928.